A 28-day multiple ascending dose study evaluating the safety and tolerability of POL6014

Trial Profile

A 28-day multiple ascending dose study evaluating the safety and tolerability of POL6014

Planning
Phase of Trial: Phase I

Latest Information Update: 12 Apr 2017

At a glance

  • Drugs POL 6014 (Primary)
  • Indications Cystic fibrosis
  • Focus Adverse reactions
  • Most Recent Events

    • 12 Apr 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top